ISB 1442: A Novel Bispecific Antibody for Targeting CD38+ Hematologic Malignancies
Antibody engineering is revolutionizing immuno-oncology, allowing for the synthesis of synthetic immunity by optimizing various components of antibody structure. Monoclonal antibodies (mAbs) and bispecific antibodies (BsAbs) with enhanced antibody effector functions haveRead More…